NASDAQ:EPZM

Epizyme News Headlines

$8.59
-0.22 (-2.50 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.39
$8.79
50-Day Range
$6.81
$9.13
52-Week Range
$6.70
$19.92
Volume1.80 million shs
Average Volume1.05 million shs
Market Capitalization$875.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.28

Epizyme (NASDAQ EPZM) News Headlines Today

SourceHeadline
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients - Business WireEpizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients - Business Wire
businesswire.com - June 16 at 8:43 AM
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma PatientsEpizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
finance.yahoo.com - June 16 at 8:43 AM
Epizymes Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models - Yahoo FinanceEpizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models - Yahoo Finance
finance.yahoo.com - June 15 at 7:44 PM
Forma Therapeutics Holdings (FMTX) Names John E. Bishop, Ph.D. CTO - StreetInsider.comForma Therapeutics Holdings (FMTX) Names John E. Bishop, Ph.D. CTO - StreetInsider.com
streetinsider.com - June 15 at 9:41 AM
Epizymes Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models - Benzinga - BenzingaEpizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models - Benzinga - Benzinga
benzinga.com - June 15 at 9:41 AM
Epizymes Multiple Myeloma Drug Candidate Inhibits Tumors In Animal ModelsEpizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models
finance.yahoo.com - June 14 at 6:32 PM
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer - StreetInsider.comForma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer - StreetInsider.com
streetinsider.com - June 14 at 8:31 AM
 Analysts Expect Epizyme, Inc. (NASDAQ:EPZM) Will Post Quarterly Sales of $8.74 Million Analysts Expect Epizyme, Inc. (NASDAQ:EPZM) Will Post Quarterly Sales of $8.74 Million
americanbankingnews.com - June 13 at 1:38 AM
 Brokerages Anticipate Epizyme, Inc. (NASDAQ:EPZM) to Announce -$0.60 EPS Brokerages Anticipate Epizyme, Inc. (NASDAQ:EPZM) to Announce -$0.60 EPS
americanbankingnews.com - June 11 at 11:16 PM
Onxeo: Report on the Combined General Meeting of June 10, 2021 - StreetInsider.comOnxeo: Report on the Combined General Meeting of June 10, 2021 - StreetInsider.com
streetinsider.com - June 10 at 3:05 PM
Epizyme (NASDAQ:EPZM) Shares Gap Up to $8.10Epizyme (NASDAQ:EPZM) Shares Gap Up to $8.10
americanbankingnews.com - June 2 at 10:55 AM
Gritstone Oncology Inc. (GRTS) Announces Changes to Its Board of Directors - StreetInsider.comGritstone Oncology Inc. (GRTS) Announces Changes to Its Board of Directors - StreetInsider.com
streetinsider.com - June 2 at 8:09 AM
Epizyme, Inc. (NASDAQ:EPZM) Given Consensus Rating of "Buy" by BrokeragesEpizyme, Inc. (NASDAQ:EPZM) Given Consensus Rating of "Buy" by Brokerages
americanbankingnews.com - May 30 at 1:32 AM
Epizyme, Inc. (NASDAQ:EPZM) Expected to Announce Quarterly Sales of $8.74 MillionEpizyme, Inc. (NASDAQ:EPZM) Expected to Announce Quarterly Sales of $8.74 Million
americanbankingnews.com - May 26 at 2:12 AM
Epizyme to Participate in Jefferies Virtual Healthcare Conference - Yahoo FinanceEpizyme to Participate in Jefferies Virtual Healthcare Conference - Yahoo Finance
finance.yahoo.com - May 25 at 12:20 PM
Epizyme to Participate in Jefferies Virtual Healthcare ConferenceEpizyme to Participate in Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 25 at 7:20 AM
Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June - Business WireEpizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June - Business Wire
businesswire.com - May 12 at 4:40 PM
Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in JuneEpizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Conferences in June
finance.yahoo.com - May 12 at 4:40 PM
Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2021 Results - Earnings Call Transcript - Seeking AlphaEpizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 8 at 5:52 PM
Epizyme Inc (EPZM) Q1 2021 Earnings Call Transcript - Motley FoolEpizyme Inc (EPZM) Q1 2021 Earnings Call Transcript - Motley Fool
fool.com - May 7 at 8:25 PM
Epizyme Inc (EPZM) Q1 2021 Earnings Call TranscriptEpizyme Inc (EPZM) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 7 at 8:25 PM
Epizymes (EPZM) Q1 Earnings Miss, Revenues Beat Estimates - NasdaqEpizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates - Nasdaq
nasdaq.com - May 7 at 10:20 AM
SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug - MarketWatchSVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug - MarketWatch
marketwatch.com - May 7 at 10:20 AM
Epizymes (EPZM) Q1 Earnings Miss, Revenues Beat EstimatesEpizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates
finance.yahoo.com - May 7 at 10:20 AM
SVB Leerink upgrades Epizyme, citing sales potential for lymphoma drugSVB Leerink upgrades Epizyme, citing sales potential for lymphoma drug
finance.yahoo.com - May 7 at 10:20 AM
Epizyme, Inc. 2021 Q1 - Results - Earnings Call PresentationEpizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 7 at 2:59 AM
Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results - Business WireEpizyme Provides Business Update and Reports First Quarter 2021 Financial Results - Business Wire
businesswire.com - May 6 at 9:50 PM
Epizyme EPS misses by $0.12, beats on revenue - Seeking AlphaEpizyme EPS misses by $0.12, beats on revenue - Seeking Alpha
seekingalpha.com - May 6 at 11:50 AM
Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates - NasdaqEpizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates - Nasdaq
nasdaq.com - May 6 at 11:50 AM
Epizyme Q1 2021 Earnings Preview - Seeking AlphaEpizyme Q1 2021 Earnings Preview - Seeking Alpha
seekingalpha.com - May 5 at 1:09 PM
Epizyme Announces Date of First Quarter 2021 Financial Results - Yahoo FinanceEpizyme Announces Date of First Quarter 2021 Financial Results - Yahoo Finance
finance.yahoo.com - April 29 at 8:48 AM
Epizyme Announces Date of First Quarter 2021 Financial ResultsEpizyme Announces Date of First Quarter 2021 Financial Results
finance.yahoo.com - April 29 at 8:48 AM
Finch Therapeutics Appoints Susan E. Graf to Board of Directors - StreetInsider.comFinch Therapeutics Appoints Susan E. Graf to Board of Directors - StreetInsider.com
streetinsider.com - April 27 at 8:21 AM
A Look At Epizymes (NASDAQ:EPZM) Share Price Returns - NasdaqA Look At Epizyme's (NASDAQ:EPZM) Share Price Returns - Nasdaq
nasdaq.com - April 27 at 8:21 AM
Chimerix Appoints Vicki Vakiener to Board of Directors - StreetInsider.comChimerix Appoints Vicki Vakiener to Board of Directors - StreetInsider.com
streetinsider.com - April 26 at 8:29 AM
2 “Strong Buy” Stocks Insiders Are Snapping Up - Nasdaq2 “Strong Buy” Stocks Insiders Are Snapping Up - Nasdaq
nasdaq.com - April 1 at 6:30 PM
Epizyme Comeback Is Likely, Price Makes It A Buy - Seeking AlphaEpizyme Comeback Is Likely, Price Makes It A Buy - Seeking Alpha
seekingalpha.com - March 30 at 8:56 PM
The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs - BenzingaThe Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs - Benzinga
benzinga.com - March 26 at 8:22 AM
EPZM Aug 2021 20.000 callEPZM Aug 2021 20.000 call
sg.finance.yahoo.com - March 25 at 8:22 PM
Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound? - Yahoo FinanceEpizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
finance.yahoo.com - March 25 at 3:22 PM
Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound?Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 25 at 3:22 PM
Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer - StreetInsider.comAura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer - StreetInsider.com
streetinsider.com - March 25 at 10:22 AM
EPZM May 2021 15.000 putEPZM May 2021 15.000 put
sg.finance.yahoo.com - March 22 at 1:30 PM
EPZM May 2021 15.000 callEPZM May 2021 15.000 call
sg.finance.yahoo.com - March 21 at 10:06 PM
EPZM May 2021 10.000 callEPZM May 2021 10.000 call
sg.finance.yahoo.com - March 21 at 5:06 PM
EPZM May 2021 25.000 callEPZM May 2021 25.000 call
sg.finance.yahoo.com - March 21 at 5:06 PM
EPZM Mar 2021 10.000 callEPZM Mar 2021 10.000 call
ca.finance.yahoo.com - March 8 at 9:55 AM
Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Companys Strategic Vision Call - Business WireEpizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company's Strategic Vision Call - Business Wire
businesswire.com - March 2 at 1:15 PM
Epizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision CallEpizyme Outlines Clinical Progress, TAZVERIK Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call
finance.yahoo.com - March 2 at 1:15 PM
The Epizyme, Inc. (NASDAQ:EPZM) Analysts Have Been Trimming Their Sales Forecasts - Yahoo FinanceThe Epizyme, Inc. (NASDAQ:EPZM) Analysts Have Been Trimming Their Sales Forecasts - Yahoo Finance
finance.yahoo.com - February 28 at 9:45 AM
This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.